echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > J Clin Oncol: Olaparib ± cediranib vs chemotherapy in recurrent platinum-sensitive ovarian cancer

    J Clin Oncol: Olaparib ± cediranib vs chemotherapy in recurrent platinum-sensitive ovarian cancer

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Ovarian cancer remains the leading cause of death for women worldwide, with approximately 313,959 cases of ovarian cancer and approximately 20,252 ovarian cancer-related deaths worldwide in 2020
    .


    Platinum-based chemotherapy is the standard of care for platinum-sensitive ovarian cancer, but complications arise with repeated platinum therapy


    ovarian cancer

    This study (NRG-GY004) was designed to evaluate the efficacy of two all-oral non-platinum drugs olaparib or olaparib/cediranib versus platinum-based chemotherapy in ovarian cancer
    .

    The NRG-GY004 study is an open-label, randomized Phase 3 trial enrolling patients with definitively diagnosed high-grade serous or endometrioid platinum-sensitive ovarian cancer
    .


    The patients were randomized (1:1:1) into three groups to receive platinum-based chemotherapy, olaparib, and olaparib/cediranib, respectively


    diagnosis

    PFS of three groups of patients

    PFS of three groups of patients

    From February 04, 2016 to November 13, 2017, a total of 565 patients were randomized into three groups
    .


    The median progression-free survival was 10.


    The median progression-free survival was 10.


    PFS in patients with BRCA mutations

    PFS in patients with BRCA mutations

    Among patients with germline BRCA mutations, the relative PFS hazard ratios were 0.
    63 and 0.
    55 for olaparib and olaparib/cediranib, respectively, compared with chemotherapy
    .


    Among patients without BRCA mutations, the relative PFS hazard ratios were 1.


    Among patients with germline BRCA mutations, the relative PFS hazard ratios were 0.


    In short, the olaparib/cediranib combination did not prolong progression-free survival in ovarian cancer patients compared with chemotherapy
    .


    However , in patients with BRCA germline mutations, both olaparib and olaparib/cediranib had significant clinical activity


    Both olaparib and olaparib/cediranib had significant clinical activity in patients with BRCA germline mutations


    Original source:

    Joyce F.


    Olaparib With or Without Cediranib Versus Platinum-Based Chemotherapy in Recurrent Platinum-Sensitive Ovarian Cancer (NRG-GY004): A Randomized, Open-Label, Phase III Trial
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.